ANSWER: B

Rationale:

Corticosteroid-induced hyperglycemia is driven primarily by GRE transactivation — the genomic arm of GR signaling in metabolically active tissues. In hepatocytes, activated GR homodimers bind GREs in the promoters of key gluconeogenic enzymes including PEPCK (the rate-limiting enzyme converting oxaloacetate to phosphoenolpyruvate) and glucose-6-phosphatase, increasing hepatic glucose production and raising fasting glucose. Simultaneously, GR transactivation in skeletal muscle and adipose tissue reduces GLUT4 expression and membrane translocation, impairing insulin-stimulated glucose uptake and creating peripheral insulin resistance. A third component — GR-mediated lipolysis with free fatty acid (FFA) release — further impairs peripheral glucose utilization through the Randle cycle. The normal serum potassium (4.1 mEq/L) confirms that mineralocorticoid receptor-mediated potassium wasting is not driving this presentation; while prednisone has modest mineralocorticoid activity, the hyperglycemia is a glucocorticoid metabolic effect mediated through GRE transactivation, not MR activation in beta cells.

• Option A: Option A is incorrect — mineralocorticoid receptor activation in pancreatic beta cells causing membrane hyperpolarization and impaired insulin secretion is not the established mechanism of corticosteroid-induced hyperglycemia. The normal potassium (4.1 mEq/L) confirms that clinically significant MR-mediated potassium wasting is absent. The primary mechanism is GRE-driven upregulation of hepatic gluconeogenesis and peripheral insulin resistance.
• Option C: Option C is incorrect — corticosteroids do not cause irreversible destruction of pancreatic beta cells through selective GR-mediated apoptosis after 8 weeks of therapy. Corticosteroid-induced diabetes frequently improves substantially with dose reduction or discontinuation, demonstrating that beta cell loss is not irreversible. Islet transplantation is not indicated for glucocorticoid-induced hyperglycemia.
• Option D: Option D is incorrect — corticosteroids do not suppress glucagon secretion from pancreatic alpha cells through GR-mediated transrepression as the mechanism of hyperglycemia. In fact, corticosteroids can increase glucagon secretion in some contexts. The established hyperglycemia mechanism is increased hepatic glucose output from upregulated gluconeogenic enzymes and reduced peripheral glucose uptake from GLUT4 downregulation.

ANSWER: D

Rationale:

Comparing the mineralocorticoid profiles: prednisone has a mineralocorticoid potency of approximately 0.8 relative to hydrocortisone (assigned potency 1.0), which at doses of 60 mg/day contributes meaningfully to sodium retention, hypertension, and volume-related symptoms. Methylprednisolone has essentially negligible mineralocorticoid activity (approximately 0.5, often cited as essentially zero in clinical pharmacology) and is therefore preferred over prednisone in situations where mineralocorticoid effects must be minimized — including patients with hypertension, congestive heart failure, or renal impairment. Dexamethasone similarly has negligible mineralocorticoid activity (approximately 0). The dose conversion for switching from prednisone to methylprednisolone uses the 5:4 equipotency ratio — prednisone 60 mg = methylprednisolone 48 mg. However, for long-term GCA maintenance therapy lasting months to years, dexamethasone carries a significant practical disadvantage: its biological half-life of 36 to 54 hours makes alternate-day dosing pharmacologically ineffective for HPA axis sparing (the off-day provides no meaningful recovery window), and it is more likely to cause severe HPA suppression than prednisone at equivalent doses. Methylprednisolone at equivalent dose achieves the mineralocorticoid reduction goal while preserving the alternate-day HPA-sparing option as the patient's GCA enters maintenance phase.

• Option A: Option A is incorrect — prednisone, methylprednisolone, and dexamethasone have meaningfully different mineralocorticoid potency profiles. Prednisone has modest but clinically relevant mineralocorticoid activity (0.8), while methylprednisolone and dexamethasone have negligible mineralocorticoid activity (approximately 0). At 60 mg/day, the difference between prednisone's mineralocorticoid effect and that of methylprednisolone is clinically important for hypertension management.
• Option B: Option B is incorrect — this option substantially misstates the mineralocorticoid potency values. Prednisone does not have a mineralocorticoid potency of 2.0 relative to hydrocortisone; its potency is approximately 0.8 (less than hydrocortisone). Methylprednisolone's potency is not exactly 0 but is essentially negligible clinically. Dexamethasone's potency is not 0.5; it is also essentially negligible. The relative ranking in this option is partially correct (prednisone > methylprednisolone in MR effect) but the numerical values are wrong.
• Option C: Option C is incorrect — dexamethasone does not have the highest mineralocorticoid potency of any synthetic corticosteroid. Dexamethasone has essentially zero clinically significant mineralocorticoid activity; its high glucocorticoid potency (25 to 30 times hydrocortisone) is entirely at the glucocorticoid receptor. Fludrocortisone holds the distinction of having by far the highest mineralocorticoid potency (125 to 150 times hydrocortisone). Switching from prednisone to dexamethasone would not worsen sodium retention and hypertension.

ANSWER: A

Rationale:

The HPA suppression threshold is well-established: any patient who has received more than 20 mg/day of prednisone (or the equivalent) for more than 3 weeks is likely to have clinically significant HPA axis suppression. This patient has received prednisone 60 mg/day — three times the threshold dose — for 10 weeks, more than three times the threshold duration. At this dose-duration combination, the degree of HPA axis suppression is not in question clinically. The hypothalamus and anterior pituitary have been under sustained, high-level glucocorticoid negative feedback, suppressing CRH pulsatility and ACTH secretion; the adrenal cortex has undergone substantial atrophy from ACTH deprivation and cannot generate the physiological cortisol surge (75 to 150 mg/day equivalent) required to survive major surgical or critical illness stress. For routine surgical planning purposes at this dose-duration combination, stress-dose coverage should be presumed necessary without requiring a morning cortisol measurement to confirm suppression. Morning cortisol testing has a role in patients near the suppression threshold (lower doses, shorter durations) where the answer is uncertain; at 60 mg/day for 10 weeks, the answer is certain.

• Option B: Option B is incorrect — once-daily morning prednisone dosing does not preserve nocturnal cortisol secretion in a way that provides stress coverage. The biological half-life of prednisolone (12 to 36 hours) means that GR occupancy at the hypothalamus and pituitary persists well into the nocturnal period after a morning dose, suppressing the normal nocturnal CRH pulsatility that drives the morning cortisol surge. After 10 weeks at 60 mg/day, the adrenal cortex is atrophied regardless of once-daily dosing timing.
• Option C: Option C is incorrect — oral prednisone is well absorbed with approximately 80% oral bioavailability, and the active metabolite prednisolone achieves systemic concentrations fully capable of GR occupancy in hypothalamic and pituitary cells. The claim that oral prednisone's first-pass metabolism prevents HPA axis suppression is pharmacologically false. Oral corticosteroids at doses above 20 mg/day for more than 3 weeks reliably suppress the HPA axis regardless of route.
• Option D: Option D is incorrect — while ACTH stimulation testing has a role in assessing HPA recovery during tapering or in patients near the suppression threshold, it is not required to justify presumptive stress-dose coverage in a patient who has clearly exceeded both the dose and duration thresholds. Requiring biochemical confirmation before stress dosing in a patient on 60 mg/day prednisone for 10 weeks introduces dangerous delay and reflects a misunderstanding of when testing adds clinical value.

ANSWER: C

Rationale:

Stress dosing protocols are calibrated to the degree of physiological stress imposed by the procedure. A colonoscopy under moderate sedation — a minimally invasive procedure with limited tissue trauma and hemodynamic stress — falls into the minor procedure category. The expected cortisol demand of minor procedures is approximately 25 to 50 mg/day cortisol equivalent, modest compared to the 75 to 150 mg/day required for major surgery. For minor procedures in a patient on chronic corticosteroids, the recommended approach is to double or triple the usual oral corticosteroid dose on the day of the procedure, provided oral intake is not restricted. This patient's usual 25 mg prednisone morning dose would be increased to approximately 50 to 75 mg on the procedure day, then returned to 25 mg the following day. This modest augmentation provides adequate cortisol coverage for the limited physiological stress of colonoscopy without exposing the patient to the risks of unnecessary parenteral high-dose hydrocortisone. The patient can take and absorb oral medications; the oral route is available and appropriate for this minor procedure.

• Option A: Option A is incorrect — postponing screening colonoscopy until complete HPA recovery in a patient on chronic corticosteroid therapy for GCA would defer an important cancer screening procedure for months to years. The claim that benzodiazepines block cortisol release through GABA receptor-mediated ACTH inhibition is pharmacologically inaccurate; benzodiazepines do not reliably suppress the adrenal cortisol response to physiological stress in a clinically meaningful way.
• Option B: Option B is incorrect — colonoscopy under moderate sedation does not constitute major surgical stress requiring full intravenous hydrocortisone stress dosing. Full IV stress coverage (hydrocortisone 100 mg IV) is reserved for major surgery under general anesthesia with significant tissue trauma and hemodynamic stress. Applying the same stress-dose protocol to a colonoscopy as to major abdominal surgery is inappropriate over-treatment.
• Option D: Option D is incorrect — although colonoscopy involves no skin incision, it does involve mild physiological stress from intestinal distension, sedation, and the procedural stress response, and a patient 4 months into high-dose prednisone therapy has significant HPA axis suppression that cannot rely on even a modest endogenous cortisol response. Complete absence of any dose modification is insufficient; doubling or tripling the oral dose is the evidence-based minor procedure approach for this patient.

ANSWER: A

Rationale:

This presentation is the ritonavir-fluticasone pharmacokinetic drug interaction — a well-documented and clinically important interaction causing iatrogenic Cushing syndrome. Fluticasone propionate has essentially zero oral bioavailability under normal circumstances: the large oropharyngeal fraction deposited during inhalation is swallowed and undergoes near-complete first-pass CYP3A4-mediated hepatic extraction before reaching systemic circulation, and the pulmonary-absorbed fraction is also rapidly cleared by CYP3A4. Ritonavir is a mechanism-based (quasi-irreversible) CYP3A4 inhibitor — it binds CYP3A4 catalytic site and forms a stable inhibitory complex that remains active for hours, effectively suppressing hepatic and intestinal CYP3A4 activity. With CYP3A4 inhibited, fluticasone's normally efficient first-pass clearance is markedly impaired; systemic fluticasone concentrations rise to levels that occupy GR in adipose tissue, skin, muscle, bone, and the neuroendocrine axis. The GR activation produces the cushingoid features (central adiposity, moon facies, striae, easy bruising, proximal myopathy) and, critically, suppresses the HPA axis through negative feedback — explaining the near-undetectable morning cortisol (0.7 μg/dL) and undetectable ACTH. The undetectable ACTH is the key discriminating feature: it confirms exogenous corticosteroid excess suppressing pituitary corticotrophs, not endogenous adrenal pathology.

• Option B: Option B is incorrect — ritonavir is an HIV protease inhibitor and CYP3A4 inhibitor; it does not bind or activate the glucocorticoid receptor as a partial agonist. Ritonavir's relevant pharmacological interaction with corticosteroids is exclusively pharmacokinetic (CYP3A4 inhibition), not pharmacodynamic (GR agonism). The undetectable ACTH confirms exogenous GR activation, not a pituitary-independent suppression mechanism.
• Option C: Option C is incorrect — endogenous Cushing disease (ACTH-secreting pituitary microadenoma) produces elevated ACTH driving bilateral adrenal cortisol hypersecretion; the cortisol would be high, not near-undetectable (0.7 μg/dL), and ACTH would be elevated or inappropriately normal, not undetectable. The clinical and laboratory profile — cushingoid features with suppressed cortisol and undetectable ACTH — is the pattern of exogenous corticosteroid excess, not endogenous Cushing disease.
• Option D: Option D is incorrect — ritonavir does not inhibit 11β-HSD1 as a primary mechanism. 11β-HSD1 converts inactive cortisone to active cortisol in hepatocytes and adipose tissue; its inhibition would reduce cortisol availability and would not produce Cushing syndrome. The presentation in this case is the opposite: corticosteroid excess, not deficiency. The mechanism is CYP3A4 inhibition allowing fluticasone accumulation, not 11β-HSD1 inhibition causing cortisol deficiency.

ANSWER: C

Rationale:

The most dangerous error in managing iatrogenic Cushing syndrome from exogenous corticosteroid excess is abrupt discontinuation of the corticosteroid source. This patient's morning cortisol of 0.7 μg/dL and undetectable ACTH confirm profound HPA axis suppression: the pituitary corticotrophs are not secreting ACTH (suppressed by months of glucocorticoid excess), and the adrenal cortex is atrophied from ACTH deprivation. If fluticasone is abruptly discontinued, the body immediately loses its only source of glucocorticoid — endogenous cortisol production cannot resume instantaneously because adrenal cortical recovery after prolonged atrophy takes weeks to months. The result is acute adrenal insufficiency (adrenal crisis): hypotension, hypoglycemia, nausea, vomiting, and cardiovascular collapse. The correct approach requires three parallel steps: (1) taper the fluticasone dose gradually to reduce the exogenous glucocorticoid exposure; (2) initiate bridging physiological hydrocortisone replacement (typically 15 to 20 mg/day in divided doses, mimicking normal cortisol output) to prevent cortisol deficiency as fluticasone is reduced; (3) monitor morning cortisol (and optionally ACTH stimulation testing) to track HPA axis recovery and guide progressive reduction of the hydrocortisone replacement. Full HPA recovery after this degree of suppression typically takes 6 to 12 months or longer.

• Option A: Option A is incorrect — abrupt fluticasone discontinuation in a patient with documented profound HPA suppression (cortisol 0.7 μg/dL) risks life-threatening adrenal crisis. The claim that adrenal glands "retain structural integrity" and will recover spontaneously without bridging is partially true structurally (the adrenal cortex is atrophied, not destroyed) but clinically dangerous — structural integrity does not translate to immediate functional capacity; cortisol secretion cannot resume quickly enough after abrupt discontinuation.
• Option B: Option B is incorrect — spironolactone blocks mineralocorticoid receptors and addresses sodium retention and hypertension related to MR activation, but it does not address the glucocorticoid receptor-mediated cushingoid features (central adiposity, proximal myopathy, striae, easy bruising). More importantly, this option fails to address the immediate management priority — the risk of adrenal crisis from continued HPA suppression if fluticasone is eventually discontinued without bridging.
• Option D: Option D is incorrect — switching the antiretroviral regimen first before addressing the fluticasone is not the correct sequence. The immediate clinical concern is the profoundly suppressed HPA axis, not the continuation of ritonavir. Furthermore, the claim that fluticasone can be abruptly discontinued once CYP3A4 inhibition resolves is incorrect — even after ritonavir is stopped, the HPA axis remains suppressed for months, and abrupt fluticasone removal without bridging still risks adrenal crisis.

ANSWER: B

Rationale:

When ICS must be used in patients on ritonavir-containing antiretroviral regimens, the goal is to select an ICS whose systemic exposure is least amplified by CYP3A4 inhibition. All currently available ICS are CYP3A4 substrates to some degree, meaning none is fully immune to this interaction. However, the magnitude of the interaction differs because systemic GR activation depends on both the systemic exposure achieved and the GR binding affinity (potency) of the agent. Fluticasone propionate has the highest GR binding affinity of any ICS combined with essentially zero oral bioavailability that is completely dependent on CYP3A4 first-pass extraction; ritonavir converts it from a non-systemic to a highly systemically active drug. Budesonide has substantially lower GR binding affinity than fluticasone and undergoes approximately 90% first-pass hepatic CYP3A4-mediated metabolism normally. With ritonavir co-administration, budesonide's systemic exposure increases, but because the starting intrinsic potency is lower and the drug accumulates to lower absolute concentrations than fluticasone at equivalent anti-asthmatic doses, the degree of systemic GR activation — and therefore the Cushing/HPA suppression risk — is substantially lower. Multiple clinical guidelines for HIV management (including those from the British HIV Association and DHHS guidelines) specifically identify budesonide DPI as the preferred ICS for patients on ritonavir-containing regimens when ICS cannot be avoided.

• Option A: Option A is incorrect — ciclesonide is not completely unaffected by CYP3A4 inhibition. While the prodrug activation step (esterase-mediated conversion to des-ciclesonide in the lung) is non-CYP, the active form des-ciclesonide is itself a CYP3A4 substrate; ritonavir inhibits its systemic clearance, increasing systemic des-ciclesonide concentrations. The claim that des-ciclesonide has essentially zero systemic bioavailability because it is irreversibly bound to lung tissue proteins is also incorrect; des-ciclesonide is absorbed systemically (though to a lesser extent than fluticasone normally), and ritonavir increases this exposure.
• Option C: Option C is incorrect — large-particle BDP does not achieve zero pulmonary absorption. While intentionally large particles (MMAD >5 μm) would deposit primarily in the oropharynx, some fraction still reaches the lungs with any inhalation effort. More importantly, BDP deposited in the oropharynx is swallowed and absorbed from the GI tract; with CYP3A4 inhibited by ritonavir, even the swallowed GI fraction would achieve systemic exposure. The stated safety mechanism is pharmacologically unsound.
• Option D: Option D is incorrect — mometasone furoate is a CYP3A4 substrate, not primarily an aldehyde oxidase substrate. While some minor metabolic pathways for mometasone may involve non-CYP enzymes, CYP3A4 is its primary clearance pathway, and ritonavir does increase mometasone systemic exposure. The claim of complete aldehyde oxidase metabolism unaffected by ritonavir is pharmacologically inaccurate.

ANSWER: D

Rationale:

Interpreting morning cortisol during HPA recovery requires understanding the two relevant thresholds. A morning cortisol below 3 μg/dL indicates significant suppression and inadequate basal adrenal function. A morning cortisol above approximately 15 to 18 μg/dL (institutional thresholds vary slightly) generally indicates adequate basal HPA axis recovery and suggests sufficient cortisol reserve for daily activities. The patient's value of 14 μg/dL falls in the indeterminate zone — it demonstrates some recovery (not severely suppressed as before) but does not reach the threshold that reliably predicts adequate stress response. The critical clinical question in a previously profoundly suppressed patient is not just basal cortisol secretion but adrenal reserve — the ability to mount the 3 to 5-fold cortisol increase required during physiological stress. The ACTH stimulation test addresses this directly: cosyntropin 250 μg IV or IM is administered, and cortisol is measured at 30 and 60 minutes. A peak cortisol above 18 to 20 μg/dL (the standard normal response threshold) confirms sufficient adrenal cortical reserve to respond to stress. A subnormal response indicates incomplete recovery despite the 14 μg/dL basal value and supports continuing sick day precautions, carrying an emergency hydrocortisone kit, and additional time before full clearance.

• Option A: Option A is incorrect — a morning cortisol of 14 μg/dL does not confirm complete HPA recovery. The value is below the threshold (approximately 15 to 18 μg/dL) that generally indicates adequate basal recovery, and it does not assess stress reserve (the more clinically important parameter for a previously profoundly suppressed patient). Discharging a patient with this cortisol from all precautions without further assessment risks undetected inadequate stress reserve.
• Option B: Option B is incorrect — a morning cortisol of 14 μg/dL reflects endogenous cortisol production, not fluticasone. Fluticasone does not cross-react with standard cortisol immunoassays (it has negligible cross-reactivity), and there is no mechanism by which fluticasone stored in adipose tissue would be measured as cortisol on a serum cortisol assay. This cortisol level represents recovering endogenous adrenal function, not residual fluticasone release.
• Option C: Option C is incorrect — a morning cortisol of 14 μg/dL is not critically low and does not indicate severe ongoing adrenal insufficiency requiring emergency hospitalization. The clinically dangerous threshold is below 3 μg/dL. A value of 14 μg/dL in an asymptomatic patient represents a recovering but incompletely recovered HPA axis that warrants formal reserve testing (ACTH stimulation), not emergency IV hydrocortisone.

ANSWER: C

Rationale:

The eosinophil count's utility as a biomarker for ICS responsiveness in COPD rests on the mechanistic link between eosinophilic airway inflammation and corticosteroid sensitivity. Eosinophilic inflammation is driven by Th2 and ILC2 (type 2 innate lymphoid cell)-derived cytokines, particularly IL-5 (the principal eosinophil differentiation, survival, and activation factor) and GM-CSF. Corticosteroids suppress this pathway through multiple GR-mediated mechanisms: NF-κB transrepression reduces IL-5 and GM-CSF gene transcription in T cells and epithelial cells; withdrawal of these survival signals triggers eosinophil apoptosis; suppression of eosinophil-recruiting chemokines (eotaxin/CCL11, CCL24) reduces tissue eosinophil accumulation; and direct GR activation in eosinophils reduces their activation state. The net result is that eosinophilic airway inflammation is highly steroid-sensitive. In contrast, neutrophil-dominant COPD inflammation (the predominant phenotype at blood eosinophil counts below 100 cells/μL) is driven by innate immune pathways including neutrophil-derived serine proteases, IL-8 (CXCL8), and reactive oxygen species. This pathway is relatively resistant to corticosteroids for multiple reasons including HDAC2 impairment by oxidative stress in COPD — damaged HDAC2 cannot deacetylate histones at NF-κB-driven promoters even when GR is activated, reducing the transrepression effect. Blood eosinophil count thus serves as a surrogate for airway inflammatory endotype, predicting which patients have steroid-sensitive inflammation (high eosinophils) versus steroid-resistant inflammation (low eosinophils).

• Option A: Option A is incorrect — blood eosinophil elevation in COPD does not exclusively indicate coexisting atopic disease with IgE-mediated mast cell sensitization. Eosinophilic COPD is a recognized inflammatory phenotype distinct from atopic asthma; not all patients with elevated COPD eosinophils have atopy. The mechanism of ICS benefit in eosinophilic COPD is GR-mediated suppression of eosinophil survival cytokines, not IgE-mast cell pathway suppression.
• Option B: Option B is incorrect — eosinophil counts above 300 cells/μL in COPD identify patients with eosinophilic (Th2/ILC2-driven) airway inflammation, not IL-17/TNF-α-driven neutrophilic inflammation. The IL-17-high inflammatory endotype is characteristically associated with neutrophilic, not eosinophilic, inflammation. The mechanism described — IL-17 upregulating GR expression to enhance ICS response — is not an established pharmacological mechanism of ICS benefit in COPD.
• Option D: Option D is incorrect — blood eosinophil counts do not predict ICS responsiveness through a mechanism involving eosinophil-mediated vascular permeability increasing ICS tissue penetration. ICS tissue penetration depends on the physicochemical properties of the drug (lipophilicity, particle size) and is not meaningfully altered by circulating eosinophil count. The predictive value of the eosinophil biomarker is pharmacodynamic (predicting which inflammatory pathway is active) not pharmacokinetic.

ANSWER: A

Rationale:

HDAC2 impairment is the best-characterized molecular mechanism of corticosteroid resistance in COPD. Under normal conditions, one key mechanism by which GR suppresses NF-κB-driven pro-inflammatory gene transcription (transrepression) is through GR-mediated recruitment of HDAC2 to the NF-κB-responsive promoters of cytokine genes (IL-8, TNF-α, IL-6). HDAC2 removes the acetyl groups from histone H4 tails at these promoters — acetylation placed there by histone acetyltransferases (HATs) during inflammatory activation — recompacting chromatin and silencing transcription. In COPD, the high oxidative stress environment generated by cigarette smoke combustion products and by activated neutrophils (which generate superoxide, peroxynitrite, and hydrogen peroxide) causes direct post-translational oxidative modifications of HDAC2 — including carbonylation of lysine residues, nitrosylation of cysteine residues, and phosphorylation by stress kinases — that reduce its enzymatic deacetylase activity. With impaired HDAC2, activated GR recruits a non-functional HDAC2 to NF-κB promoters; the histone acetylation marks that maintain chromatin in the open pro-inflammatory state are not removed; and cytokine gene transcription continues despite GR activation. The practical result is that corticosteroid doses effective in asthma (where HDAC2 is intact) are insufficient to suppress airway inflammation in COPD (where HDAC2 is damaged). Sub-bronchodilator doses of theophylline have been shown to restore HDAC2 activity in some studies, partially restoring corticosteroid sensitivity in COPD.

• Option B: Option B is incorrect — IL-8 (CXCL8) does not competitively inhibit GR ligand binding by occupying the GR ligand-binding pocket. IL-8 is a CXC chemokine that binds CXCR1 and CXCR2 G-protein-coupled receptors on neutrophil surfaces; it has no structural homology with glucocorticoids and cannot bind the GR steroid-binding pocket. Corticosteroid resistance in neutrophilic COPD is not explained by competitive displacement from GR.
• Option C: Option C is incorrect — neutrophil elastase has not been established as a cause of GR-α N-terminal cleavage producing a truncated receptor that selectively loses transactivation capacity while retaining transrepression in COPD airways. While neutrophil elastase does cleave many extracellular and matrix proteins, selective intracellular GR cleavage by neutrophil elastase as an established mechanism of COPD corticosteroid resistance is not supported in the pharmacological literature.
• Option D: Option D is incorrect — while JNK-mediated phosphorylation of GR at Ser226 has been described in some experimental models as reducing nuclear translocation efficiency, this is not the primary established mechanism of COPD corticosteroid resistance. Complete failure of GR nuclear translocation in neutrophilic COPD is not the clinically or experimentally documented mechanism. The HDAC2 impairment pathway, operating at the level of chromatin remodeling at pro-inflammatory promoters after GR nuclear entry, is the most established mechanism.

ANSWER: D

Rationale:

Oropharyngeal candidiasis from ICS is a local adverse effect caused by residual drug depositing on oropharyngeal mucosal surfaces during inhalation. Regardless of total ICS dose or systemic plasma concentrations, approximately 60 to 90% of an inhaled dose (depending on device and technique) deposits in the oropharynx and is swallowed. Active ICS deposited in the oropharynx activates GR in local mucosal epithelial cells, macrophages, and lymphocytes. GR activation suppresses local innate and adaptive immune responses — reducing mucosal macrophage phagocytic function, attenuating neutrophil chemokine-driven recruitment to mucosal surfaces, and suppressing epithelial antimicrobial peptide production — creating a local immunosuppressed microenvironment that allows Candida albicans (commensal yeast normally present in low numbers) to proliferate. This mechanism operates independently of systemic corticosteroid levels; it is driven by local drug-receptor interaction at the oropharyngeal deposition site. Standard preventive strategies (spacer use, mouth rinsing) reduce the amount of drug depositing in the oropharynx. The intrinsic pharmacological prevention is ciclesonide, a prodrug that is inactive at the oropharyngeal mucosa because esterase-mediated activation to the active form des-ciclesonide requires the specific esterase activity present in bronchial epithelial cells; the oropharynx and gastrointestinal tract lack sufficient esterase activity to activate the prodrug, so oropharyngeal deposition produces no GR activation and no local immunosuppression.

• Option A: Option A is incorrect — at standard ICS doses (even higher doses of fluticasone in COPD), the systemic fluticasone concentrations achieved after normal CYP3A4-mediated clearance are too low to produce clinically significant systemic T cell immunosuppression. ICS-related oropharyngeal candidiasis is a local effect from oropharyngeal drug deposition, not a systemic immunosuppression effect. Switching to lower-affinity ICS solely to reduce systemic levels would not address the local oropharyngeal deposition mechanism.
• Option B: Option B is incorrect — corticosteroids do not suppress parasympathetic salivary gland function through GR-mediated mechanisms. ICS do not have anticholinergic activity. Salivary flow reduction is not an established mechanism of ICS-related candidiasis. The local GR activation at the oropharyngeal mucosa — not salivary flow reduction — is the established mechanism.
• Option C: Option C is incorrect — umeclidinium (LAMA) does cause dry mouth through M3 muscarinic receptor antagonism in salivary glands, which can theoretically contribute to oral Candida risk by reducing antimicrobial saliva. However, the primary cause of oral candidiasis in ICS users is oropharyngeal ICS deposition and local GR activation — not the LAMA component. The dysphonia in this patient reflects local corticosteroid effects on laryngeal muscles (a well-recognized ICS adverse effect), not LAMA-induced laryngeal anticholinergic effects.

ANSWER: B

Rationale:

The systemic effects of high-dose ICS — including modest bone loss — are dose-dependent and clinically relevant at the upper end of the ICS dosing range. While standard low- and medium-dose ICS have minimal systemic effects due to near-complete first-pass hepatic CYP3A4 extraction, high-dose ICS (fluticasone ≥500 μg/day, budesonide ≥800 μg/day) achieve low but pharmacologically non-trivial systemic glucocorticoid concentrations that can produce measurable HPA axis suppression and contribute to bone loss over years. Multiple studies and meta-analyses have documented small but statistically significant reductions in bone mineral density with high-dose ICS use, particularly at the lumbar spine and femoral neck. The mechanism is the same as oral glucocorticoid-induced osteoporosis: systemic GR activation in osteoblasts and bone marrow stromal cells upregulates RANKL and downregulates OPG, increasing osteoclast-mediated bone resorption. In this patient, 3 years of high-dose fluticasone combined with postmenopausal estrogen deficiency (which independently reduces OPG expression and increases RANKL) has produced cumulative bone loss resulting in osteoporosis at two sites. A bisphosphonate (alendronate 70 mg once weekly or risedronate 35 mg once weekly orally, or zoledronic acid 5 mg IV annually) is indicated at a T-score of −2.8 alongside calcium and vitamin D, consistent with current osteoporosis treatment guidelines and GIOP prevention guidelines.

• Option A: Option A is incorrect — high-dose ICS do produce measurable systemic glucocorticoid exposure sufficient to contribute to bone loss, particularly at doses of fluticasone ≥500 μg/day. While the systemic exposure from ICS is substantially less than equivalent anti-inflammatory oral corticosteroid doses, it is not zero, and the cumulative effect over 3 years of high-dose therapy contributes meaningfully to bone loss. Managing her osteoporosis as purely postmenopausal without ICS consideration misses an important modifiable contributor.
• Option C: Option C is incorrect — ICS at standard doses are not completely free of systemic effects; high-dose ICS do have measurable systemic effects on bone and the HPA axis. While COPD-related systemic inflammation (elevated CRP, IL-6, TNF-α) does independently contribute to bone loss in COPD, increasing ICS dose to address systemic inflammation would worsen ICS-related bone loss and is not a pharmacologically rational approach. The intervention for bone loss is bisphosphonate therapy.
• Option D: Option D is incorrect — ICS-related bone loss affects trabecular bone preferentially, including the lumbar spine — not exclusively cortical bone. The lumbar spine is rich in trabecular bone and is highly sensitive to glucocorticoid-induced bone loss through the RANKL/OPG mechanism, which primarily affects trabecular microarchitecture. The lumbar spine T-score of −2.8 is entirely consistent with glucocorticoid-related bone loss and does not require bone marrow biopsy to exclude malignancy before bisphosphonate initiation in a postmenopausal woman with known ICS exposure.

ANSWER: D

Rationale:

Rifampin is the most potent CYP3A4 inducer encountered in clinical practice, acting through activation of the pregnane X receptor (PXR) in hepatocytes and intestinal enterocytes. PXR activation drives transcriptional upregulation of CYP3A4, dramatically increasing the liver's capacity to oxidatively metabolize CYP3A4 substrates. Prednisolone is a CYP3A4 substrate; the principal route of its hepatic and intestinal metabolism involves CYP3A4-mediated oxidation to inactive metabolites (6β-hydroxyprednisolone being the predominant product). When rifampin is added, the markedly elevated CYP3A4 activity accelerates prednisolone clearance, reducing plasma prednisolone area under the curve (AUC) by approximately 50 to 75% in most patients. The clinical consequence is pharmacokinetic inadequacy of the usual dose: the patient who was well-controlled on prednisolone 30 mg/day may effectively receive the equivalent of 10 to 15 mg/day in terms of systemic exposure, risking lupus nephritis flare from inadequate immunosuppression. The prednisolone dose must be increased — typically two- to threefold — during rifampin co-administration, with the understanding that the dose must be reduced back toward baseline when rifampin is discontinued (over 2 to 4 weeks as CYP3A4 activity normalizes) to avoid rebound cushingoid effects.

• Option A: Option A is incorrect — rifampin is a PXR-activating CYP3A4 inducer, not an OATP1B1 inhibitor in the context of corticosteroid interactions. Rifampin does inhibit OATP1B1 as an acute effect, which is relevant for statins (whose plasma levels can transiently rise with rifampin initiation); however, this does not increase prednisolone plasma levels. The dominant rifampin-prednisolone interaction is CYP3A4 induction reducing prednisolone clearance, not OATP inhibition increasing it.
• Option B: Option B is incorrect — rifampin does not competitively displace prednisolone from CBG binding sites as a clinically significant pharmacokinetic interaction. Rifampin's relevant interaction with corticosteroids is CYP3A4 induction, not protein binding displacement. CBG displacement is not an established mechanism of rifampin-corticosteroid pharmacokinetic interaction.
• Option C: Option C is incorrect — prednisolone is metabolized primarily by CYP3A4-mediated phase I oxidation, not exclusively by phase II glucuronidation. Rifampin does induce UGT enzymes in addition to CYP enzymes through PXR activation, but the primary rifampin-prednisolone interaction is CYP3A4 induction. The claim that only phase I CYP enzymes are induced by rifampin is also inaccurate — rifampin via PXR induces both CYP and UGT enzyme families.

ANSWER: B

Rationale:

The correct approach to the rifampin-prednisolone interaction is proactive dose escalation at the time of rifampin initiation, not waiting for disease evidence of under-immunosuppression before acting. Because rifampin's CYP3A4 induction is pharmacokinetically predictable and well-quantified (50 to 75% reduction in prednisolone AUC), the clinical team can anticipate the interaction and increase the prednisolone dose preemptively to maintain equivalent immunosuppressive exposure. A two- to threefold dose increase (from 30 mg/day to approximately 60 to 90 mg/day) roughly compensates for the 50 to 75% reduction in plasma exposure. Monitoring for lupus disease activity (creatinine, 24-hour urine protein or spot urine protein:creatinine ratio, urinary sediment for casts, complement levels, anti-dsDNA) allows clinical adjustment. When rifampin is completed after 4 months, CYP3A4 induction resolves over approximately 2 to 4 weeks as the induced enzyme protein is degraded; during this normalization period, the higher prednisolone dose will produce progressively increasing plasma concentrations as CYP3A4 activity falls back to baseline. The dose must therefore be tapered back toward the original 30 mg/day level over this 2 to 4 week period to avoid iatrogenic cushingoid effects from the resolving CYP3A4 induction.

• Option A: Option A is incorrect — prednisolone plasma levels do not increase with rifampin co-administration. Rifampin induces CYP3A4, which accelerates prednisolone metabolism and reduces (not increases) plasma prednisolone concentrations. Reducing the prednisolone dose upon starting rifampin would compound the pharmacokinetic under-exposure and risk serious lupus flare.
• Option C: Option C is incorrect — while measuring plasma prednisolone levels is a pharmacokinetically sound approach in principle, waiting 2 weeks after rifampin initiation to assess levels and then adjusting introduces a 2-week window of potential under-immunosuppression in a patient with lupus nephritis. In diseases with life- or organ-threatening potential, proactive dose adjustment at the time of the known interaction is preferable to reactive adjustment after demonstrated pharmacokinetic inadequacy. Additionally, prednisolone plasma level monitoring (Cmax measurement) is not routinely available in most clinical settings.
• Option D: Option D is incorrect — dexamethasone is a CYP3A4 substrate, not primarily an aldehyde reductase substrate. Rifampin does induce CYP3A4-mediated dexamethasone clearance, and dexamethasone plasma levels are reduced by rifampin co-administration to a similar degree as prednisolone. Dexamethasone is not a rifampin-safe corticosteroid on the basis of being CYP3A4-independent.

ANSWER: C

Rationale:

This scenario illustrates the under-recognized but clinically important reverse consequence of the rifampin-prednisolone interaction: Cushing syndrome developing after rifampin is stopped due to failure to reduce the compensatory prednisolone dose. When rifampin was initiated, CYP3A4 induction reduced prednisolone plasma exposure by 50 to 75%, requiring a dose increase to approximately 75 mg/day to maintain adequate immunosuppression. Rifampin exerts CYP3A4 induction through upregulation of enzyme protein synthesis; when rifampin is discontinued, the induced enzyme persists until the excess CYP3A4 protein is degraded. This normalization takes approximately 2 to 4 weeks. During this period, CYP3A4 activity gradually declines back to baseline, and prednisolone clearance progressively slows. If the prednisolone dose of 75 mg/day is maintained unchanged, the patient receives increasing effective prednisolone exposure as clearance normalizes — effectively receiving the equivalent of 150 to 225 mg/day prednisolone (two- to threefold higher than the original 30 mg/day) by the time full CYP3A4 normalization is complete. This explains the rapid-onset cushingoid features (weight gain, moon facies, hyperglycemia) 2 weeks after rifampin completion. Correct management: taper prednisolone from 75 mg/day back to approximately 30 mg/day over 2 to 4 weeks, monitoring for lupus disease activity during the taper to ensure adequate immunosuppression is maintained.

• Option A: Option A is incorrect — delayed hypersensitivity to rifampin causing GR hypersensitivity is not an established pharmacological mechanism. The presentation is explained entirely by the expected pharmacokinetic consequence of rifampin CYP3A4 induction resolution — not by an immunological or receptor sensitivity mechanism. Antihistamines have no role in managing this pharmacokinetic complication.
• Option B: Option B is incorrect — the physician increased the prednisolone dose from 30 to 75 mg/day specifically to compensate for rifampin-induced CYP3A4 induction, not because of lupus relapse; this was the correct clinical management during the rifampin course. The cushingoid presentation 2 weeks after rifampin completion is explained by the restoration of normal prednisolone plasma levels as CYP3A4 activity normalizes — the 75 mg dose is now delivering full therapeutic exposure that was previously being cleared. The management is a gradual taper, not an abrupt return to 30 mg.
• Option D: Option D is incorrect — there is no 6 to 12-month GR recalibration period following rifampin-induced CYP3A4 induction. GR expression and sensitivity normalize rapidly after corticosteroid level normalization; the physiological recalibration period does not explain the acute cushingoid presentation or justify maintaining 75 mg/day indefinitely. The correct action is dose reduction.

ANSWER: A

Rationale:

Alternate-day corticosteroid therapy achieves HPA sparing by creating a 24-hour low-GR-occupancy window during the off-day period (exploiting prednisolone's 12 to 36 hour biological half-life and the 48-hour dosing interval to allow partial pituitary CRH/ACTH axis recovery). This approach works well in inflammatory conditions where the target inflammatory cells do not rapidly reconstitute their pathological activity during the off-day window — particularly eosinophilic conditions (eosinophils undergo apoptosis and are not rapidly replaced) and some lymphocyte-mediated conditions. In lupus nephritis, the situation is different. The pathological inflammation involves ongoing autoantibody production by long-lived plasma cells and memory B cells, continuous immune complex formation and deposition in glomeruli, and complement-mediated glomerular injury — processes that can resume within hours when corticosteroid levels fall. B cell activity, in particular, can reconstitute rapidly during off-day periods when GR-mediated transrepression of B cell cytokine production and plasma cell differentiation signals is withdrawn. Clinical experience and rheumatological guidelines generally advise against alternate-day corticosteroid therapy as the primary management strategy for lupus nephritis, particularly during induction and early maintenance phases, because of the risk of nephritis flare on off-days. The HPA-sparing benefits of alternate-day therapy are thus not achievable at an acceptable risk of disease flare in this condition.

• Option B: Option B is incorrect — a single prednisolone dose of 60 mg (which would be the alternate-day equivalent of 30 mg/day) does not cause irreversible ACTH receptor downregulation in pituitary corticotroph cells. Irreversible HPA suppression is not caused by any individual dose at clinical doses; HPA suppression is a cumulative effect of sustained negative feedback over weeks. Additionally, the 40 mg "irreversibility threshold" described does not correspond to any established pharmacological concept.
• Option C: Option C is incorrect — this option confuses plasma half-life with biological half-life. Prednisolone's plasma half-life is approximately 2 to 3.5 hours (reflecting drug concentration kinetics), but its biological half-life — the duration of GR-mediated transcriptional effects in target tissues — is 12 to 36 hours. It is the biological half-life that determines whether pharmacological effects bridge the alternate-day dosing interval, and 12 to 36 hours is sufficient to sustain meaningful GR occupancy across a 48-hour cycle in many conditions.
• Option D: Option D is incorrect — mycophenolate mofetil does not require simultaneous corticosteroid GR activation for its T cell-suppressive efficacy. Mycophenolic acid (the active form) inhibits IMPDH (inosine monophosphate dehydrogenase), blocking de novo purine synthesis and selectively suppressing lymphocyte proliferation through a GR-independent mechanism. Mycophenolate functions normally on off-days in alternate-day corticosteroid regimens.

ANSWER: B

Rationale:

Acute severe asthma in pregnancy is managed identically to acute severe asthma in non-pregnant patients with respect to systemic corticosteroids — because the risks of untreated severe asthma to both mother and fetus substantially exceed the risks of a short course of systemic corticosteroid. Uncontrolled severe asthma causes maternal hypoxemia (SpO2 89% in this case), which directly compromises fetal oxygen delivery; fetal hypoxia is a more immediate and serious risk than the corticosteroid exposure. IV methylprednisolone 40 to 80 mg or oral prednisolone 40 to 50 mg are equivalent evidence-based options for acute severe asthma management and are both appropriate in pregnancy. Regarding fetal exposure: the placenta expresses 11β-HSD2, which inactivates prednisolone (the active form of prednisone) and cortisol to their inactive 11-keto metabolites, significantly reducing fetal drug exposure. This placental barrier provides an additional safety margin for prednisolone and methylprednisolone (which are also partially inactivated by 11β-HSD2) compared to fluorinated agents like betamethasone and dexamethasone, which are specifically used when fetal organ maturation is desired (such as antenatal corticosteroid therapy). The theoretical risk of cleft palate from first-trimester corticosteroid exposure — based on older teratogenicity data — does not apply to short courses in the second/third trimester for acute severe illness.

• Option A: Option A is incorrect — corticosteroids are not absolutely contraindicated in pregnancy, particularly for acute life-threatening asthma. The cleft palate association is a low-risk finding primarily associated with first-trimester systemic exposure; it does not preclude emergency use at 27 weeks gestational age. This patient's severe acute asthma requires immediate systemic corticosteroid treatment. IV methylprednisolone is appropriate and is used in pregnancy when indicated.
• Option C: Option C is incorrect — high-dose inhaled fluticasone at 2,000 μg/day via spacer does not provide equivalent acute bronchial anti-inflammatory effect to systemic methylprednisolone within 15 minutes. ICS requires hours to produce genomic anti-inflammatory effects (GR transactivation of anti-inflammatory genes and transrepression of NF-κB require mRNA transcription and protein synthesis). ICS does not substitute for systemic corticosteroids in the acute management of severe asthma.
• Option D: Option D is incorrect — dexamethasone is not preferred over methylprednisolone or prednisolone for acute asthma in pregnancy. Dexamethasone is specifically used as an antenatal corticosteroid for fetal lung maturation because it crosses the placenta (poor 11β-HSD2 substrate), which is the opposite of desirable for acute maternal asthma treatment. Furthermore, the claim that methylprednisolone triggers placental CRH release through its 11β-hydroxyl group is pharmacologically unfounded.

ANSWER: D

Rationale:

The placental 11β-HSD2 barrier is the central pharmacological concept explaining differential fetal exposure to different corticosteroids. 11β-HSD2 is a NAD+-dependent oxidase that converts active 11β-hydroxyl glucocorticoids (cortisol, prednisolone, methylprednisolone) to their inactive 11-keto forms (cortisone, prednisone, 11-ketobudesonide respectively). This enzymatic barrier is highly expressed in the syncytiotrophoblast of the human placenta and serves a critical physiological purpose: protecting the fetal HPA axis and growth programming from the much higher maternal cortisol concentrations that would otherwise cause fetal HPA suppression and growth restriction. The consequence for pharmacology is that maternal prednisolone (and to a lesser degree methylprednisolone) crosses the placenta only partially intact — a significant fraction is inactivated by 11β-HSD2 before reaching fetal tissue. This is why prednisolone is considered relatively safe for treating maternal inflammatory conditions during pregnancy: the placenta protects the fetus from most of the maternal drug. However, this same barrier means prednisolone is NOT appropriate for intentional fetal organ maturation — too little intact drug reaches the fetal lung at standard maternal dosing. Betamethasone and dexamethasone are fluorinated at position 9, making them poor substrates for 11β-HSD2; they cross the placenta largely intact and achieve fetal tissue concentrations sufficient to induce surfactant synthesis. Inhaled fluticasone similarly does not provide meaningful fetal lung maturation benefit; its small systemically absorbed fraction undergoes 11β-HSD2 processing during placental transfer.

• Option A: Option A is incorrect — inhaled fluticasone does not reach fetal circulation through direct alveolar absorption into the uteroplacental circulation. The uteroplacental circulation is a blood supply system, not a direct alveolar-to-fetal pathway. Systemically absorbed fluticasone (from the pulmonary fraction) reaches the systemic maternal circulation and then crosses the placenta to some degree; however, it is subject to 11β-HSD2 inactivation. Oral prednisolone is not entirely metabolized in the liver before reaching the placenta; prednisolone is well absorbed and reaches systemic circulation intact before placental transfer.
• Option B: Option B is incorrect — the reason betamethasone and dexamethasone are specifically used for antenatal lung maturation is their poor 11β-HSD2 substrate status (allowing placental passage intact), not because of structural features creating unique fetal pulmonary GR interactions that prednisolone cannot replicate. Fetal pulmonary GR responds normally to prednisolone and cortisol; the issue is concentration — 11β-HSD2 prevents sufficient prednisolone from reaching the fetal lung at maternal therapeutic doses.
• Option C: Option C is incorrect — fluticasone does not activate vitamin D receptors (VDR) as a mechanism of fetal surfactant induction. Fluticasone is a glucocorticoid receptor agonist; it does not bind VDR or have structural similarity to vitamin D metabolites. Surfactant protein synthesis in fetal alveolar type II cells is induced through GR activation (by both glucocorticoids and thyroid hormones), not through a glucocorticoid-independent VDR pathway.

ANSWER: A

Rationale:

Antenatal corticosteroid therapy for fetal lung maturation uses betamethasone 12 mg IM every 24 hours for two doses (or dexamethasone 6 mg IM every 12 hours for four doses) — specifically fluorinated corticosteroids that cross the placenta largely intact. The pharmacological rationale is that both betamethasone and dexamethasone are poor substrates for placental 11β-HSD2, which oxidizes 11β-hydroxyl corticosteroids (cortisol, prednisolone, methylprednisolone) to inactive 11-keto forms. Because betamethasone and dexamethasone resist this inactivation, they cross the placenta at concentrations sufficient to activate GR in fetal type II alveolar cells, inducing surfactant phospholipid and protein synthesis (surfactant protein B, C, and D), thinning alveolar walls, and accelerating lung maturation. Methylprednisolone, despite being administered systemically to the mother, is subject to significant 11β-HSD2-mediated inactivation during placental transfer; the fraction reaching the fetal circulation intact is insufficient to achieve the fetal lung surfactant induction that betamethasone provides. The systemic maternal corticosteroid course does not substitute for specifically selected antenatal agents. This pharmacological distinction explains a seemingly counterintuitive clinical situation: a mother receiving IV methylprednisolone requires a separate betamethasone IM injection for fetal lung maturation because the two drugs serve pharmacologically distinct functions based on their 11β-HSD2 substrate status.

• Option B: Option B is incorrect — prednisolone is not the recommended antenatal corticosteroid for fetal lung maturation. As described above, prednisolone is substantially inactivated by placental 11β-HSD2, reducing fetal drug concentrations to below those required for surfactant induction. The standard agents are betamethasone and dexamethasone. The claim that betamethasone is not recommended in UK and US guidelines is incorrect; betamethasone is the primary recommendation in most international guidelines including RCOG and ACOG.
• Option C: Option C is incorrect — the ongoing IV methylprednisolone does not provide adequate fetal lung corticosteroid exposure to substitute for antenatal betamethasone therapy. As explained, placental 11β-HSD2 inactivates a substantial fraction of maternal methylprednisolone before it reaches the fetal lung. Betamethasone injection is specifically required to achieve fetal surfactant induction and is not redundant with maternal methylprednisolone therapy.
• Option D: Option D is incorrect — dexamethasone's biological half-life is approximately 36 to 54 hours, not 72 to 96 hours, and betamethasone has a comparable biological half-life. The four-dose dexamethasone regimen is used because each 6 mg dose is smaller than the 12 mg betamethasone dose, achieving equivalent total exposure across the course while allowing more frequent assessment; it is not because dexamethasone has a shorter biological half-life requiring more frequent dosing to match betamethasone's duration.

ANSWER: C

Rationale:

Antenatal betamethasone crosses the placenta largely intact (being a poor 11β-HSD2 substrate) and reaches the fetal circulation at pharmacologically active concentrations — which is precisely the therapeutic mechanism for fetal lung maturation. These concentrations are also sufficient to suppress the fetal HPA axis through GR-mediated negative feedback at the fetal hypothalamus and pituitary, reducing fetal CRH and ACTH secretion and consequently fetal adrenal cortisol output. This produces a transient state of secondary HPA suppression that is an expected consequence of antenatal corticosteroid therapy. The clinical presentation — low cortisol and hypoglycemia in the first few days of life — is recognized in the neonatal literature as a consequence of antenatal corticosteroid exposure, particularly with multiple courses or when delivery occurs shortly after administration. The suppression is secondary (structural adrenal integrity is preserved; ACTH drive is transiently reduced by exogenous corticosteroid feedback) and self-limiting: as betamethasone is cleared from the neonatal circulation (biological half-life 36 to 54 hours; neonatal clearance may be slower), the fetal/neonatal HPA axis recovers. Management is supportive — dextrose infusion for hypoglycemia, and low-dose hydrocortisone (1 to 2 mg/kg/day) if hypoglycemia is severe or persistent; prolonged corticosteroid replacement is not required as the axis recovers within days to weeks.

• Option A: Option A is incorrect — maternal methylprednisolone is substantially inactivated by placental 11β-HSD2, reducing its fetal exposure compared to betamethasone. Methylprednisolone does not cross the placenta at higher concentrations than betamethasone; the pharmacological relationship is the opposite. The antenatal betamethasone (not the maternal methylprednisolone) is the primary contributor to neonatal HPA suppression. Furthermore, 6 to 12 months of hydrocortisone replacement is not required for transient HPA suppression from antenatal steroid exposure.
• Option B: Option B is incorrect — betamethasone does not cause direct cytotoxic destruction of fetal adrenal cortical cells. The transient HPA suppression is a pharmacodynamic GR-mediated negative feedback effect, not structural adrenal damage. This suppression is temporary and reversible; it does not produce permanent adrenal insufficiency requiring lifelong replacement.
• Option D: Option D is incorrect — while prematurity is associated with relative adrenal immaturity, the low cortisol in this specific clinical context cannot be attributed purely to gestational age without accounting for the antenatal betamethasone exposure. The clinical finding of hypoglycemia requiring dextrose indicates that the cortisol level is functionally inadequate, not merely a normal developmental variant. The antenatal corticosteroid-related HPA suppression is the primary explanation and should be communicated to the family.

ANSWER: C

Rationale:

Corticosteroid-induced myopathy is one of the most common causes of proximal muscle weakness in patients on chronic or high-dose corticosteroids and must be distinguished from inflammatory myopathies (polymyositis, dermatomyositis, IMNM) that would require immunosuppression escalation rather than corticosteroid reduction. The mechanism is GRE-driven transactivation: activated GR in skeletal muscle cells upregulates the transcription of muscle-specific E3 ubiquitin ligase genes — including MuRF1 (muscle RING finger protein 1, encoded by TRIM63) and Atrogin-1 (also called MAFbx, muscle atrophy F-box, encoded by FBXO32) — that tag myofibrillar proteins (particularly myosin heavy chain, actin) for proteasomal degradation. This protein catabolism preferentially affects type IIb (fast-twitch glycolytic) muscle fibers, which have higher metabolic activity and greater sensitivity to glucocorticoid-mediated atrophy signals than type I (slow-twitch oxidative) fibers. The clinical signature of corticosteroid myopathy includes: painless symmetric proximal weakness (hip flexors, shoulder abductors most affected), preserved distal strength, normal serum CK (muscle fiber atrophy through ubiquitin-proteasome degradation does not disrupt the sarcolemmal membrane and therefore does not release CK into circulation), and type II fiber atrophy on muscle imaging (selective signal change in type IIb fiber-dominant regions) and biopsy. The EMG typically shows myopathic changes (small-amplitude, polyphasic motor unit potentials) without fibrillation potentials or positive sharp waves (no denervation). Management is corticosteroid dose reduction when feasible and exercise therapy.

• Option A: Option A is incorrect — tacrolimus-induced peripheral neuropathy is a recognized adverse effect of calcineurin inhibitors and can cause neurogenic weakness. However, neurogenic weakness presents with asymmetric or distal predominance, and EMG shows denervation findings (fibrillation potentials, positive sharp waves) rather than myopathic changes. The EMG in this patient shows myopathic changes without denervation, and the weakness is symmetric and proximal — consistent with myopathy, not peripheral neuropathy.
• Option B: Option B is incorrect — mycophenolate mofetil does not cause a recognized mitochondrial myopathy through IMPDH inhibition in skeletal muscle. IMPDH inhibition affects lymphocyte proliferation; it is not associated with significant skeletal muscle mitochondrial dysfunction or inflammatory myopathy. The claim that mycophenolate causes elevated CK suppressed by prednisone is pharmacologically unfounded.
• Option D: Option D is incorrect — immune-mediated necrotizing myopathy (IMNM) associated with anti-SRP antibodies characteristically presents with markedly elevated CK (often 10 to 50 times the upper limit of normal) and necrotizing myopathy on biopsy. A normal CK essentially excludes active necrotizing myopathy regardless of concomitant prednisone. Furthermore, tacrolimus does not trigger anti-SRP antibody production as a recognized adverse effect.

ANSWER: A

Rationale:

These two corticosteroid-related bone complications are mechanistically distinct and require different preventive approaches, which is why bisphosphonates effectively reduce GIOP fracture risk but do not prevent osteonecrosis. GIOP mechanism: In osteoblasts and bone marrow stromal cells, GRE-driven transactivation upregulates RANKL expression and simultaneously downregulates OPG (osteoprotegerin, the RANKL decoy receptor); the resulting increase in the RANKL/OPG ratio drives osteoclast differentiation and activation, increasing bone resorption. Simultaneously, corticosteroids suppress osteoblast proliferation, differentiation, and survival (through multiple GR-mediated mechanisms), reducing bone formation. The net effect is diffuse trabecular bone loss that bisphosphonates effectively counteract by inhibiting osteoclast function (via farnesyl pyrophosphate synthase inhibition and promotion of osteoclast apoptosis). Osteonecrosis mechanism: Corticosteroids promote adipogenic differentiation of bone marrow mesenchymal stem cells through GRE-driven upregulation of master adipogenic transcription factors PPARγ (peroxisome proliferator-activated receptor gamma) and C/EBPα (CCAAT/enhancer-binding protein alpha), filling bone marrow with hypertrophied adipocytes that increase intraosseous pressure and compress small venous sinusoids. Simultaneously, corticosteroids may promote fat emboli in small subchondral arteriolar vessels, causing focal ischemia and osteocyte death in the pressure-sensitive subchondral zone of the femoral head. Because bisphosphonates target osteoclasts and do not address the adipogenic or vascular mechanisms of osteonecrosis, they cannot prevent this complication.

• Option B: Option B is incorrect — osteonecrosis does not result from hyperactivated osteoclasts at the subchondral surface; it results from vascular compromise and ischemia causing osteocyte death. If osteoclast hyperactivation were the mechanism, bisphosphonates would prevent osteonecrosis by inhibiting osteoclasts, which they do not. GIOP does involve osteoclast activation through RANKL/OPG imbalance (not exclusively osteocyte apoptosis), and bisphosphonates do address this effectively.
• Option C: Option C is incorrect — osteonecrosis and GIOP are not caused by the same RANKL/OPG mechanism applied to different anatomical locations. Osteonecrosis is a vascular-ischemic and adipogenic process; GIOP is an osteoclast-driven resorption plus osteoblast suppression process. Their different mechanistic bases explain why bisphosphonates prevent GIOP but not osteonecrosis, which would not be the case if the mechanisms were identical with only anatomical distribution differing.
• Option D: Option D is incorrect — while corticosteroid-induced VEGF suppression is a real phenomenon and may contribute to avascular complications, attributing osteonecrosis exclusively to VEGF suppression in subchondral endothelial cells oversimplifies the established multi-mechanism model. The bisphosphonate mechanism described — preventing GIOP by downregulating sclerostin through SOST gene transcription effects — is pharmacologically inaccurate. Bisphosphonates work through inhibition of the mevalonate pathway (farnesyl pyrophosphate synthase) in osteoclasts, not through sclerostin downregulation.

ANSWER: D

Rationale:

Both cyclosporine and tacrolimus are calcineurin inhibitors that suppress T cell activation by inhibiting the calcineurin-NFAT pathway, but they have meaningfully different effects on the CYP3A4 enzyme system. Cyclosporine is a substrate for CYP3A4 and also inhibits CYP3A4 (and the efflux transporter P-glycoprotein) with moderate to significant potency; co-administration of cyclosporine with corticosteroids (CYP3A4 substrates) increases plasma corticosteroid concentrations by reducing corticosteroid clearance, potentially amplifying corticosteroid adverse effects including cushingoid features, hyperglycemia, HPA suppression, and osteoporosis. Tacrolimus is also a CYP3A4 substrate but exerts less CYP3A4 inhibitory activity than cyclosporine on a weight-adjusted comparison; the pharmacokinetic amplification of corticosteroid exposure is therefore less pronounced with tacrolimus co-administration. This pharmacokinetic difference is one factor (among several including different toxicity profiles, dosing convenience, and transplant outcome data) that has contributed to tacrolimus becoming the predominant calcineurin inhibitor in modern transplant immunosuppression protocols. The clinical implication is that patients on cyclosporine-based regimens may experience more pronounced corticosteroid adverse effects at identical corticosteroid doses compared to tacrolimus-based regimens.

• Option A: Option A is incorrect — tacrolimus does not upregulate CYP3A4 through PXR activation; this describes the mechanism of CYP3A4 inducers such as rifampin and carbamazepine. Tacrolimus is a CYP3A4 substrate, not a CYP3A4 inducer. Cyclosporine inhibits (rather than induces) CYP3A4, increasing rather than decreasing corticosteroid plasma levels; the directional claim in this option is reversed.
• Option B: Option B is incorrect — while it is true that cyclosporine has more adverse effects on lipid profiles than tacrolimus (including LDL elevation through mechanisms involving LDL receptor downregulation), the specific mechanism described — HMG-CoA reductase upregulation by cyclosporine — is not the established mechanism. HMG-CoA reductase is the target of statins; its upregulation would increase cholesterol synthesis, which is directionally consistent with hypercholesterolemia, but the established mechanism of cyclosporine-related hyperlipidemia involves LDL receptor downregulation and inhibition of bile acid synthesis rather than HMG-CoA reductase induction.
• Option C: Option C is incorrect — tacrolimus does not act as a GR co-agonist in T cells, and cyclosporine does not block GR nuclear import. Both calcineurin inhibitors suppress T cells through the calcineurin-NFAT pathway, which is entirely distinct from the glucocorticoid receptor pathway. The interaction between calcineurin inhibitors and corticosteroids is pharmacokinetic (CYP3A4 substrate/inhibitor), not pharmacodynamic (GR modulation).

ANSWER: B

Rationale:

Bisphosphonate selection in CKD requires balancing fracture prevention benefit against renal safety risk. All bisphosphonates are cleared renally; at reduced eGFR, higher plasma concentrations are achieved after a given dose, and bisphosphonate accumulation in renal tubules can cause tubular toxicity. The renal safety thresholds differ between oral and intravenous bisphosphonates. Oral weekly bisphosphonates (alendronate, risedronate) are absorbed from the GI tract in small fractional doses (oral bioavailability approximately 0.5 to 2%), and the renal exposure per dose is modest; they can be used cautiously in CKD stage 3 (eGFR 30 to 59 mL/min) with renal monitoring, and prescribing information for alendronate and risedronate generally permits use down to eGFR 30 to 35 mL/min. Intravenous bisphosphonates (particularly zoledronic acid 5 mg annually), administered as a bolus IV infusion, deliver a much larger concentration of drug to the renal tubules over a short period; this peak tubular concentration is associated with acute tubular necrosis when administered too rapidly or in patients with pre-existing CKD. The prescribing information for zoledronic acid 5 mg (Reclast) recommends avoiding use at eGFR below 35 mL/min for the osteoporosis indication. For this patient at eGFR 38 mL/min — just above the IV zoledronic acid threshold but in CKD stage 3b — oral alendronate or risedronate represents the safer and guideline-consistent choice with renal function monitoring.

• Option A: Option A is incorrect — alendronate is not cleared exclusively by tubular secretion independent of GFR. Bisphosphonate renal handling involves both glomerular filtration and tubular processes; the statement that alendronate is unaffected by GFR at any level above 10 mL/min is pharmacologically incorrect. Alendronate prescribing information recommends caution at eGFR below 35 mL/min and avoiding at eGFR below 30 mL/min.
• Option C: Option C is incorrect — IV zoledronic acid 5 mg is specifically associated with higher renal tubular toxicity risk than oral bisphosphonates at equivalent reduced GFR, not lower. Prescribing information for zoledronic acid 5 mg recommends avoiding it at eGFR below 35 mL/min for the osteoporosis indication; using it at eGFR 38 mL/min is near the threshold and requires careful consideration. It is not the preferred choice over oral agents in this patient.
• Option D: Option D is incorrect — there is no American Society of Transplantation black-box warning against all bisphosphonate use at eGFR below 45 mL/min, and denosumab is not categorically the first-line anti-resorptive in all renal transplant patients with CKD stage 3. While denosumab can be used in CKD (it is not renally cleared), it requires careful monitoring for hypocalcemia (particularly in CKD) and has a prolonged rebound effect on bone resorption if discontinued. Oral bisphosphonates at appropriate doses remain a valid option in CKD stage 3b with monitoring.

ANSWER: A

Rationale:

Interpreting HPA function tests requires understanding the specific thresholds and what each test measures. The morning cortisol at 8 am (drawn before that day's prednisone) reflects basal HPA axis function at the time of day when endogenous cortisol output is highest — the natural morning peak. A value below 3 μg/dL indicates severe suppression with inadequate even basal cortisol output. A value above approximately 15 to 18 μg/dL (institutions vary) indicates adequate basal recovery. The patient's value of 4.2 μg/dL falls in the indeterminate zone — she has some endogenous cortisol production but well below what a fully recovered axis would generate. The ACTH stimulation test (cosyntropin 250 μg IV) directly tests adrenal cortical reserve — the capacity to mount a cortisol response to ACTH stimulation, simulating the stress response. A normal response is defined as a peak cortisol above 18 to 20 μg/dL at 30 or 60 minutes. Her peak of 13.1 μg/dL at 60 minutes is subnormal — her adrenal cortex cannot adequately respond to maximal ACTH stimulation, confirming impaired stress reserve. The practical implication: at rest, she can maintain adequate basal cortisol from her recovering adrenal axis. Under physiological stress — febrile illness, surgery, trauma — the cortisol demand rises to 75 to 150 mg/day equivalent, which her adrenal cortex cannot generate. She remains at risk for adrenal crisis during stress events. The taper should continue slowly, and sick day rules (doubling the prednisone dose during illness) and an emergency hydrocortisone injection kit should be maintained until a repeat ACTH stimulation test shows a normal response.

• Option B: Option B is incorrect — neither the morning cortisol of 4.2 μg/dL nor the ACTH stimulation test peak of 13.1 μg/dL confirms complete HPA recovery. The relevant thresholds are: morning cortisol above 15 to 18 μg/dL for basal recovery, and stimulated peak above 18 to 20 μg/dL for adequate stress reserve. Both values fall below their respective thresholds. A stimulated cortisol above 10 μg/dL is not the established normal response cutoff; 18 to 20 μg/dL is the standard threshold.
• Option C: Option C is incorrect — the ACTH stimulation test pattern described is consistent with secondary adrenal insufficiency (from prolonged exogenous corticosteroid suppression), not primary adrenal insufficiency (Addison disease). In primary adrenal insufficiency, the adrenal cortex is destroyed and cannot respond to any ACTH; the 13.1 μg/dL stimulated response, while subnormal, shows partial adrenal cortical function. Additionally, a 3-year prednisone course does not "unmask" pre-existing Addison disease; it causes secondary HPA suppression. Primary adrenal insufficiency produces elevated ACTH (not the low ACTH of secondary HPA suppression), and fludrocortisone replacement would not be required for secondary adrenal insufficiency (aldosterone production through the RAAS is preserved).
• Option D: Option D is incorrect — prednisone 5 mg/day is not uniformly a "physiological replacement dose" that reliably avoids HPA axis suppression. While 5 mg/day is near the physiological cortisol output equivalent (approximately 5 to 7.5 mg/day prednisone), 3 years of continuous exogenous corticosteroid administration — even at low doses — can produce variable degrees of HPA suppression and adrenal atrophy. This patient's morning cortisol of 4.2 μg/dL and subnormal ACTH stimulation response confirm that her axis is not intact despite the low dose and do not support an assumption of normal function.

ANSWER: C

Rationale:

The physiological replacement range for corticosteroids is approximately 5 to 7.5 mg/day of prednisone (equivalent to the normal daily cortisol production of approximately 8 to 10 mg/day). When a patient reaches this dose during tapering, the exogenous corticosteroid is no longer supplementing above physiological levels — it is filling the gap left by the suppressed adrenal axis's inability to generate endogenous cortisol. Below 5 mg/day, each further reduction creates an increasing cortisol deficit that the recovering adrenal cortex must incrementally replace through gradually restored ACTH responsiveness and cortisol synthesis. The challenge is that adrenal cortical recovery after prolonged suppression is slow — weeks to months — and the recovering axis cannot rapidly increase cortisol output to fill a gap created by a large, fast dose reduction. A reduction from 5 mg to 4 mg represents a 20% decrease in total corticosteroid cover; if the adrenal axis cannot generate that additional 1 mg equivalent endogenously within the same day, the patient experiences transient relative cortisol insufficiency (fatigue, nausea, arthralgia, mild hypotension). Reducing by only 1 mg every 1 to 2 weeks gives the adrenal axis time to incrementally restore enough cortisol output to compensate for each small reduction before the next reduction is made. This is fundamentally different from the earlier taper from 15 mg to 5 mg, where the reductions were still above the physiological range and the cortisol deficit at each step was filled by the diminishing but still supraphysiological exogenous dose still on board.

• Option A: Option A is incorrect — prednisone does not have a non-linear absorption mechanism below 5 mg due to saturation of a low-affinity mucosal transporter. Prednisone absorption from the GI tract is passive diffusion-based (as for all lipophilic steroids) and does not have a transporter-saturable kinetic at low doses. The bioavailability of prednisone is approximately 80% across the clinical dose range and does not fall sharply below 5 mg.
• Option B: Option B is incorrect — there is no pharmacological mechanism by which prednisone at doses below 7.5 mg/day competitively displaces endogenous cortisol from GR, producing paradoxical GR hypersensitivity when doses are reduced. Corticosteroid withdrawal syndrome (fatigue, arthralgias, myalgias) that occurs during tapering reflects relative cortisol deficiency from HPA axis suppression, not receptor hypersensitivity from cortisol displacement.
• Option D: Option D is incorrect — HPA axis suppression through GR-mediated negative feedback at the hypothalamus and pituitary occurs across the full dose range of prednisone above physiological levels; it is not a phenomenon that begins for the first time at exactly 5 mg/day. ACTH secretion is suppressed throughout the patient's therapy, not only below 5 mg. The claim that IL-6-mediated ACTH suppression is the mechanism first activated at 5 mg/day is pharmacologically unfounded.

ANSWER: B

Rationale:

Sick day rule counseling is a mandatory component of care for any patient who has received chronic corticosteroids above the HPA suppression threshold and whose HPA recovery is incomplete — as confirmed in this patient by the subnormal ACTH stimulation test. The physiological rationale is that normal daily cortisol output (approximately 8 to 10 mg/day equivalent) increases 3 to 5 fold during significant physiological stress. If the adrenal axis cannot generate this increase endogenously, the exogenous corticosteroid dose must be increased to cover the deficit. For minor illnesses with fever (temperature above approximately 38.5°C) or significant intercurrent illness, the standard guidance is to double or triple the usual oral corticosteroid dose and maintain the higher dose until the illness resolves, then return to the usual dose. This applies to febrile illnesses, significant injuries, and any physiological stress beyond the ordinary. The emergency injection indication is specifically when the oral route becomes unavailable — vomiting, inability to swallow, loss of consciousness, or any condition preventing oral absorption. In these circumstances, the patient cannot rely on oral prednisone reaching systemic circulation and must immediately administer the emergency injection (hydrocortisone 100 mg IM from the prefilled kit) and call for emergency medical assistance. The 100 mg hydrocortisone dose is chosen because at this dose, hydrocortisone provides both adequate glucocorticoid effect (approximately equivalent to prednisone 25 mg) and sufficient mineralocorticoid activity (from hydrocortisone's inherent MR activity) to support blood pressure during the acute crisis.

• Option A: Option A is incorrect — sick day rules apply to febrile illnesses and gastroenteritis as well as surgical stress; these are precisely the scenarios where adrenal crisis most commonly occurs in patients with HPA suppression. Febrile illness increases cortisol demand substantially. The claim that adrenal axis reserves are sufficient at prednisone 5 mg/day for all non-surgical stresses is contradicted by this patient's subnormal ACTH stimulation test. Withholding sick day dose adjustments for illness would expose her to adrenal crisis risk.
• Option C: Option C is incorrect — sick day rules do apply at prednisone 5 mg/day when HPA recovery is incomplete, as demonstrated by this patient's test results. The threshold for sick day precautions is not defined by a minimum prednisone dose but by the HPA axis's ability to respond to stress — which this patient has confirmed is inadequate. The statement that the emergency kit should only be used after formal medical consultation introduces a dangerous delay for a life-threatening emergency.
• Option D: Option D is incorrect — the emergency injection kit contains hydrocortisone, not betamethasone. Hydrocortisone is specifically used because it has both glucocorticoid and mineralocorticoid activity, providing hemodynamic support as well as metabolic coverage during adrenal crisis. Betamethasone has negligible mineralocorticoid activity and is not the standard emergency injection agent for adrenal crisis. Additionally, betamethasone is the antenatal corticosteroid agent and is not used for adrenal crisis management.

ANSWER: D

Rationale:

This question requires applying stress dosing principles to a specific clinical scenario in a patient at the very end of her taper with borderline HPA recovery. For minor procedures (gastroscopy under moderate sedation involves minimal tissue trauma and limited hemodynamic stress), the standard approach in a patient with residual HPA suppression is to double or triple the usual oral corticosteroid dose on the day of the procedure, provided the oral route is available before the procedure. At 3 mg/day, doubling to 6 mg provides modest additional coverage for the limited physiological stress of gastroscopy. The borderline ACTH stimulation test result (15.8 μg/dL — approaching but not reaching the 18 to 20 μg/dL normal threshold) adds a nuance: while her cortisol reserve is nearly normal, the prudent approach is to inform the procedural team and have parenteral hydrocortisone 100 mg immediately available for emergency use if the patient develops unexpected hemodynamic instability during or after the procedure. This "oral double-dose plus standby IV" approach balances the minor nature of the procedure against the documented, albeit borderline, impairment in stress reserve. The patient does not require full prophylactic IV stress-dose coverage (which is appropriate for major surgery), but preparedness for rapid IV treatment if needed reflects appropriate management of the residual uncertainty.

• Option A: Option A is incorrect — a patient with a documented subnormal ACTH stimulation test (15.8 μg/dL peak, below the 18 to 20 μg/dL normal threshold) on prednisone 3 mg/day retains measurable impairment of stress cortisol reserve. Although the degree of impairment is modest and approaching normal, taking no precautionary action ignores the confirmed impairment. Doubling the oral dose on the procedure day is a simple, low-risk precaution that should not be omitted.
• Option B: Option B is incorrect — postponing all endoscopic procedures until ACTH stimulation test normalization would result in indefinite deferral of clinically important diagnostic procedures in many patients with slow HPA recovery. Moderate sedation agents (including propofol) do not produce clinically significant GR-level suppression of residual ACTH secretion; this is not an established pharmacological mechanism that would contraindicate endoscopy in patients with recovering HPA function.
• Option C: Option C is incorrect — a gastroscopy under moderate sedation does not constitute major physiological stress requiring full prophylactic IV stress-dose coverage (100 mg hydrocortisone + 50 mg IV every 6 hours for 24 hours). This regimen is appropriate for major surgery with general anesthesia, significant tissue trauma, and major hemodynamic stress. Applying the same protocol to a diagnostic gastroscopy is inappropriate over-treatment that exposes the patient unnecessarily to high-dose corticosteroid adverse effects and would further delay HPA axis recovery. ANSWER KEY CASE 1: Q1: B | Q2: D | Q3: A | Q4: C CASE 2: Q1: A | Q2: C | Q3: B | Q4: D CASE 3: Q1: C | Q2: A | Q3: D | Q4: B CASE 4: Q1: D | Q2: B | Q3: C | Q4: A CASE 5: Q1: B | Q2: D | Q3: A | Q4: C CASE 6: Q1: C | Q2: A | Q3: D | Q4: B CASE 7: Q1: A | Q2: C | Q3: B | Q4: D